Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04094259
Other study ID # 87RI19-0020 (ALTER-MAI)
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 9, 2019
Est. completion date December 1, 2021

Study information

Verified date August 2022
Source University Hospital, Limoges
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients followed in Internal Medicine bring together favorable conditions for the use of alternative medicines. While some are recognized for their benefits, some can, on the contrary, harm the patient. It is therefore proposed to make a complete descriptive inventory of these practices, through an anonymized questionnaire. The main objective is the evaluation of the proportion of the use of alternative medicines in patients with in the department of Internal Medicine A


Description:

Patients followed in Internal Medicine department bring together favorable conditions for the use of alternative medicines. While some are recognized for their benefits, some can, on the contrary, harm the patient. It is therefore proposed to make a complete descriptive inventory of these practices, through an anonymized questionnaire. The main objective is the evaluation of the proportion of the use of alternative medicines in patients with autoimmune diseases in the department of Internal Medicine . At all times alternative medicine has existed. Internal Medicine deals with rare autoimmune diseases, of which there is not always a cure. Even when the treatment is optimal, there are often subjective complaints.Patients followed in Internal Medicine therefore have favorable conditions for the use of alternative medicines. While some are recognized for their benefits, some can, on the contrary, harm the patient. It is therefore proposed to make a complete descriptive inventory of these practices, through an anonymized questionnaire. This information will make it possible to target the patient's needs, and to be able to offer alternative medicines that are better focused, without calling into question their conventional treatment


Recruitment information / eligibility

Status Completed
Enrollment 121
Est. completion date December 1, 2021
Est. primary completion date December 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: - Patient with systemic lupus erythematosus (ARA and/or SLICC criteria) OR with primary Sjögren's syndrome (revised Americano European criteria) OR with systemic scleroderma (ACR/EULAR 2012 criteria) - Patient with signed consent Exclusion criteria: - Patients deprived of their liberty - Minors and adults subject to legal protection measures - Patients subject to a justice safeguard measure - Patient unable to understand or adhere to the protocol

Study Design


Intervention

Behavioral:
Questionnaire.
patients will respond to a specific questionnaire regarding the use of alternative medicine

Locations

Country Name City State
France Médecin Interne A Limoges

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Limoges

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary The number of patients using alternative medicine. Counting the number of patients using alternative medicine. At day 1